Chi Sheng Pharma & Biotech Balance Sheet Health
Financial Health criteria checks 5/6
Chi Sheng Pharma & Biotech has a total shareholder equity of NT$1.2B and total debt of NT$120.0M, which brings its debt-to-equity ratio to 9.8%. Its total assets and total liabilities are NT$1.8B and NT$547.0M respectively. Chi Sheng Pharma & Biotech's EBIT is NT$61.2M making its interest coverage ratio -4. It has cash and short-term investments of NT$381.0M.
Key information
9.8%
Debt to equity ratio
NT$120.00m
Debt
| Interest coverage ratio | -4x |
| Cash | NT$381.05m |
| Equity | NT$1.22b |
| Total liabilities | NT$547.04m |
| Total assets | NT$1.77b |
Recent financial health updates
No updates
Recent updates
Read This Before Buying Chi Sheng Pharma & Biotech Co., Ltd (GTSM:4111) For Its Dividend
Apr 06
A Look At The Fair Value Of Chi Sheng Pharma & Biotech Co., Ltd (GTSM:4111)
Mar 10Should Weakness in Chi Sheng Pharma & Biotech Co., Ltd's (GTSM:4111) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?
Feb 01
Here's What You Should Know About Chi Sheng Pharma & Biotech Co., Ltd's (GTSM:4111) 4.2% Dividend Yield
Jan 05Estimating The Fair Value Of Chi Sheng Pharma & Biotech Co., Ltd (GTSM:4111)
Dec 10Financial Position Analysis
Short Term Liabilities: 4111's short term assets (NT$804.0M) exceed its short term liabilities (NT$451.5M).
Long Term Liabilities: 4111's short term assets (NT$804.0M) exceed its long term liabilities (NT$95.6M).
Debt to Equity History and Analysis
Debt Level: 4111 has more cash than its total debt.
Reducing Debt: 4111's debt to equity ratio has increased from 3.3% to 9.8% over the past 5 years.
Debt Coverage: 4111's debt is well covered by operating cash flow (62.1%).
Interest Coverage: 4111 earns more interest than it pays, so coverage of interest payments is not a concern.